MARKETS LIVE: Wall Street in the green as investors weigh Anthropic IPO filing
SpaceX committed to a $40B lease for Nvidia chips. Xencor shares rose 20% on positive drug trial results. Surgery Partners surged 46% after a $5.7B acquisition deal. Tesla gained 6% following a Barclays upgrade. Verizon raised 2026 guidance after strong customer additions. Anthropic filed for IPO, with concerns raised about its valuation and spending. FTSE 100 gained 0.7%. Big Tech earnings and Fed decision are key focuses this week.
How this was made
The 30-second read
Why it matters
Anthropic's S‑1 filing is the primary market‑moving event, while the other company updates provide secondary catalysts.
Market read
Anthropic's IPO filing is the headline catalyst, with several other corporate updates providing additional trading ideas across tech, biotech, and telecom sectors.
What to watch
Potential regulatory scrutiny on AI spending and the competitive landscape for biotech pipelines could temper enthusiasm.
Background
The article is a live market update covering multiple corporate events and the Anthropic IPO filing.
Ticker impact
SpaceX committed to a $40B finance lease for Nvidia chips, indicating a large new spend that could affect SpaceX's balance sheet and Nvidia demand.
likely downside as investors digest the large financing obligation
The $40B lease is a material liability; investors may view it as a risk to cash flow.
Xencor shares jumped 20% after updated kidney‑cancer trial data showed a 45.5% tumour response, supporting Phase 3 plans.
upward pressure as the trial data validates the pipeline
Strong response rate is a material clinical‑trial milestone for a biotech.
Barclays upgraded Tesla to overweight and raised its price target to $450, sending the stock up 6%.
further upside as the upgrade may attract more buyers
Upgrade reflects improved fundamentals but may be partially priced in already.
Verizon raised its 2026 guidance for post‑paid phone additions after adding 406,000 customers in Q3, its strongest in five years.
slight upward pressure as investors value the subscriber growth
Guidance improvement is positive but modest in scale.
BioVie will present Phase 2 results for its Long COVID drug bezisterim at a government‑backed workshop.
potential volatility around the workshop outcome
No results yet; market awaits the data.
Market effects
AI‑related spending and biotech trial data could influence tech and healthcare sector sentiment.
U.S. market likely to see modest gains from the positive corporate news, while European markets may be muted.
The Anthropic IPO filing adds to overall AI hype, supporting a global risk‑on bias.
Counterpoint
The large lease by SpaceX may strain cash flow, and the Tesla upgrade could be over‑optimistic given macro headwinds.
Key entities
- companyAnthropic
AI startup filing for an IPO, subject of the article title.
- companySpaceX
Committed to a $40B finance lease for Nvidia chips.
- companyXencor
Biotech reporting strong kidney‑cancer trial data.
- companySurgery Partners
Target of a $5.7B acquisition by HealthSpan Partners.
- companyTesla
Received a Barclays upgrade to overweight.
